Hanmi Pharmaceutical Advances Six New Drugs into Clinical Trials Targeting Hypertension, Diabetes, and Cancer
Key Insights
Hanmi Pharmaceutical is progressing HCP1803, a novel low-dose triple antihypertensive drug, through Phase 3 clinical trials in Korea, expected to conclude in the second half of next year.
The company launched Raspirin, an antithrombotic drug, this year, expanding its product line to offer diverse treatment options for healthcare providers and patients.
Hanmi's U.S.-based biologic Rolvedon, a cancer (search) drug, generated $55.6 million in sales last year, with ongoing efforts to expand its global reach in Asia, Africa, and the U.S.
Hanmi Pharmaceutical has announced that six of its new and improved drugs, targeting conditions such as hypertension (search), dyslipidemia (search), diabetes (search), and musculoskeletal disorders, have entered Phase 1-3 clinical trials.
Novel Antihypertensive: HCP1803
Hanmi is developing HCP1803, Korea's first low-dose triple antihypertensive drug, to broaden its hypertension (search) portfolio. This drug employs a novel approach by simultaneously blocking multiple pathological pathways. The Phase 3 clinical trial is actively progressing in Korea and is anticipated to conclude in the second half of the following year.
Data from the HCP1803 study was presented at the European Society of Hypertension (search) (ESH) congress in Berlin, Germany, in June. The study suggests that a low-dose combination of three antihypertensive components can be an effective initial treatment for hypertension.
Expanding Product Line
Hanmi Pharmaceutical continues to introduce new and improved combination drugs. Following the launch of the diabetes (search) drug Sildapa in September of the previous year, the company launched the antithrombotic drug Raspirin in February of this year. This expansion aims to provide a range of treatment options for healthcare providers and patients through multiple doses and various combinations.
Rolvedon's Global Expansion
Hanmi Pharmaceutical's U.S.-based biologic, Rolvedon, a cancer (search) drug, generated $55.6 million in sales last year and $14.5 million and $15.1 million in the first and second quarters of this year, respectively. The company is actively pursuing opportunities in Asia, Africa, and the U.S. to ensure the successful global sale of Rolvedon.
Efpeglenatide Development
Hanmi Pharmaceutical has also decided to develop the returned biologic drug efpeglenatide into a Korean-specific GLP-1 obesity drug. Following the lead drug efpeglenatide, clinical and non-clinical developments of the projects within the “HOP Project” are also on track.
Park Jae-hyun, CEO of Hanmi Pharmaceutical, stated, “Improved and compounded drugs with pharmaceutical manufacturing capabilities and excellent formulation technology are key assets and driving forces for our company's growth as we move firmly toward developing innovative new drugs. We will continue to develop high-quality and competitive drugs unique to Hanmi and move forward as a global R&D-centered pharmaceutical company representing Korea.”